drugset / Trial / NCT02387164

Prevention Trial: Immune-tolerance With Alum-GAD (Diamyd) and Vitamin D3 to Children With Multiple Islet Autoantibodies

NCT02387164

Phase 2 Terminated 26 enrolled Lund University Region Skane · collab
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to evaluate if immune-tolerance with Alum-formulated GAD (Diamyd), in combination with high dose Vitamin D3, may delay or stop the autoimmune process leading to clinical type 1 diabetes in non-diabetic children with ongoing beta-cell autoimmunity as indicated by positive islet autoantibodies.

Timeline

Start
2015-03-09
Primary completion
2019-10-07
Completion
2019-10-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject GAD-Alum Vaccine 20 ug Subcutaneous
Background Cholecalciferol Other / unclassified 2000 iu